l e t t e r s
The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway is critical for cellular growth and metabolism. Correspondingly, loss of function of PTEN, a negative regulator of PI3K, or activating mutations in AKT1, AKT2 or AKT3 have been found in distinct disorders featuring overgrowth or hypoglycemia. We performed exome sequencing of DNA from unaffected and affected cells from an individual with an unclassified syndrome of congenital progressive segmental overgrowth of fibrous and adipose tissue and bone and identified the cancer-associated mutation encoding p.His1047Leu in PIK3CA, the gene that encodes the p110a catalytic subunit of PI3K, only in affected cells. Sequencing of PIK3CA in ten additional individuals with overlapping syndromes identified either the p.His1047Leu alteration or a second cancer-associated alteration, p.His1047Arg, in nine cases. Affected dermal fibroblasts showed enhanced basal and epidermal growth factor (EGF)-stimulated phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) generation and concomitant activation of downstream signaling relative to their unaffected counterparts. Our findings characterize a distinct overgrowth syndrome, biochemically demonstrate activation of PI3K signaling and thereby identify a rational therapeutic target.
Mutations that compromise the regulation of cellular proliferation and death by reducing apoptosis or by allowing constitutive cell division cause pathological tissue growth. The most extreme example is cancer, where numerous activating mutations of genes in growthpromoting pathways have been documented. A commonly affected pathway is the receptor tyrosine kinase (RTK)-PI3K-AKT pathway, which harbors activating mutations in most solid tumors 1 .
Given the importance of RTK-PI3K-AKT signaling for cell proliferation and metabolism, germline mutations upregulating the pathway would likely be lethal during embryonic development and have not been reported. However, mosaic mutations can cause segmental, or patchy, overgrowth disorders. Germline loss-of-function mutations in PTEN, a negative regulator of PI3K signaling, cause overgrowth, and a somatic second hit in PTEN causes the type 2 segmental Cowden syndrome 2 . Proteus syndrome, a progressively deforming regional overgrowth syndrome that affects bones, adipose and other mesenchymal tissues, is caused by a somatic AKT1 mutation encoding a p.Glu17Lys alteration 3 , which constitutively activates PI3K-AKT signaling 3, 4 . These findings support the hypothesis that segmental overgrowth disorders can be caused by somatic mosaicism for mutations 5 and suggested that similar disorders may also be caused by somatic activation of the RTK-PI3K-AKT pathway. We describe here the clinical and molecular characterization of ten such affected individuals.
Ten individuals with a previously uncharacterized progressive segmental overgrowth syndrome were evaluated (Supplementary Note).
Of those for whom records were available, seven of eight had congenital overgrowth. Their major manifestation was segmental progressive overgrowth of subcutaneous, muscular and visceral fibroadipose tissue with skeletal overgrowth (Figs. 1 and 2) . Overgrowth was predominantly of adipose tissue or was a mixture of adipose and fibrous tissues. We have thus termed the affected tissues 'fibroadipose' tissue. In some affected areas, this tissue was solitary, but in others there was admixture of the fibroadipose tissue with muscle or investiture within other tissues Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA l e t t e r s (for example, spinal canal). The range of severity and of natural history among the affected individuals was notable. Subject C1 had massive overgrowth of her body from the waist down, weighing 117 kg, with leg circumferences of 100-110 cm. Her total adiposity, assessed by dualenergy X-ray absorptiometry (DXA), was 50%, accounted for mostly by her legs. Her overgrowth continued into adulthood. In contrast, subject C2 had overgrowth limited to an arm and thumb, and subject N110 had overgrowth limited to two rays of one foot (Fig. 2o,p) . Subject N7 had an extensive lipoma of the left lower trunk, buttock and leg that necessitated amputation (Fig. 1f,g ). Subject N45 had fibroadipose overgrowth of the lower body, including a pelvic mass that encased the rectum (Fig. 2j) with attendant constipation. The overgrowth in this individual continued into adulthood. However, the overgrowth in subject N68 mostly ceased after puberty.
Eight of the ten affected individuals have undergone multiple surgical debulking or orthopedic procedures for overgrowth. Skeletal overgrowth was variable in character. Four individuals had skeletal overgrowth with preserved architecture, whereas others had distorting overgrowth (Fig. 2) . Subject N45 underwent orthopedic surgery to correct a 5-cm discrepancy in leg length. Bone ages, when assessed, were normal, and no dental anomalies were reported. Several individuals had enlarged peripheral nerves, cutaneous vascular malformations and testicular or epididymal cysts and hydroceles. Four individuals had marked lipoatrophy in areas not affected by overgrowth, but no evidence for either insulin resistance or hypoglycemia was reported. None of the affected individuals had reported malignancies, although subject N108 did have benign nephrogenic rests.
All subjects had been suggested to have Proteus syndrome; however, according to our evaluation, none met the clinical criteria for this condition 6 (Table 1) , and seven of the ten had congenital segmental overgrowth, which is rare in Proteus syndrome. None had a cerebriform connective tissue nevus. Another diagnostic consideration is Klippel-Trenaunay syndrome (KTS). However, the vascular anomalies in the present individuals comprised only capillary vascular malformations, and none of the individuals had the lateral venous anomaly or port wine stains typical of KTS 7 . Furthermore, overgrowth in the present individuals was not coincident with the vascular anomalies, which is characteristic of KTS. All individuals had apparently normal intellectual and pubertal development, and one has two unaffected children.
Exome sequencing of dermal fibroblast DNA from the unaffected arm and affected leg of subject C1 identified 45 nonsynonymous genetic variants unique to leg-derived fibroblasts and absent in dbSNP and 894 controls. Sanger sequencing of DNA from freshly cultured dermal fibroblasts from a second skin biopsy confirmed only two of these leg-specific genetic variants: the heterozygous mutations in PIK3CA c.3140A>T (rs121913279; encoding p.His1047Leu) and USHBP1 c.280C>G (encoding p.Glu94Gln) ( Fig. 3 and Supplementary Fig. 1 ). USHBP1 encodes a putative Usher syndrome-related USH1C-binding protein that is highly expressed in the heart, and no link between USHBP1 and the overgrowth phenotype was found in the existing literature. In contrast, PIK3CA encodes the p110α catalytic subunit of growth factorregulated signal-transducing PI3K, and p.His1047Leu has been reported in >130 cancers in the Catalogue of Somatic Mutations in Cancer (COSMIC), whereas the mutation encoding a p.His1047Arg alteration-the most common cancer-associated PIK3CA mutation 8 -stimulates both PI3K signaling and cell growth. This mutation was selected for further study.
Sequencing of DNA from five tissues obtained from the amputated left leg of subject C1 confirmed the PIK3CA mutation at all sites, with mutation burdens determined to be from 8-39% (Fig. 3 and Supplementary Table 1) using a custom restriction enzyme-based assay ( Supplementary Fig. 2 and Supplementary Table 2 ). To determine whether mutations at codon 1047 might underlie similar forms of overgrowth, we undertook targeted sequencing in ten other individuals with overgrowth syndromes with overlapping clinical features to those of subject C1. In nine of ten subjects, mosaicism for mutations in PIK3CA codon 1047 was identified. The cancer-associated PIK3CA variant p.His1047Arg was identified in seven of the nine affected individuals, with mutation burdens ranging from <1% to 35% in affected tissues and fibroblast cultures (Supplementary Table 1 ). The p.His1047Leu alteration was identified in two out of the nine subjects, with mutation burdens ranging from 4-49%. Mutations were absent in blood and unaffected tissues from nine of the reported affected individuals, from both parents of six of these individuals and from 51 cell or tissue control samples.
The identified PIK3CA mutations were absent in >5,000 samples in the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project. In the ClinSeq data set (712 exomes), there were 21 variant sequence reads at codon 1047 among >92,000 reads, although no sample had >1 variant read. In 1000 Genomes Project data (933 low-coverage genomes) 9 , there were >5,000 wild-type reads and one variant read. npg l e t t e r s Both the p.His1047Arg and p.His1047Leu PIK3CA variants result in higher kinase activity due to enhanced lipid binding [10] [11] [12] . We thus assessed PI3K activity in dermal fibroblasts from three affected individuals by applying a mass spectroscopy assay for PIP 3 (ref. 10) before and after stimulation of cells with EGF. PIP 3 levels were 2-4 times higher in affected cells relative to unaffected cells at baseline and in response to EGF stimulation (Fig. 4) , and basal PIP 3 levels in affected cells were indistinguishable from those in control cells after stimulation. Basal hyperphosphorylation of downstream AKT and p70 S6 kinases were detected in cells with mutant PIK3CA. No signal amplification or induction of phosphorylation was observed in affected cells, reflecting the fact that the signaling cascade is already at maximum stimulation capacity in these cells. There was no increase in signaling through the MEK-extracellular-regulated kinase (ERK) pathway (Fig. 4) . We conclude that these affected individuals harbor somatically mutated cells with enhanced basal activity of the PI3K-AKT pathway.
Our description of ten individuals with a previously uncharacterized severe segmental overgrowth syndrome due to somatic occurrence of activating mutations that affect the p110α catalytic subunit of PI3K consolidates the paradigm of non-Mendelian, non-malignant growth disorders caused by isolated cancer-associated mutations in the PI3K-AKT signaling pathway. Moreover, the finding of distinct and homogeneous underlying genetic defects in stringently defined Proteus syndrome, which is caused by somatic activation of AKT1, as well as in the currently delineated syndrome, offers a mechanismbased validation of existing diagnostic criteria for Proteus syndrome. The syndrome we delineate does not fulfill the specific diagnostic criteria for Proteus syndrome 13 , instead falling within the poorly defined category of segmental overgrowth 14 . Attempts have been made to divide this group in to subclasses, and the affected individuals reported here may be within category III of a recently proposed system 15 . However, we believe that future refinement of the npg l e t t e r s understanding of the phenotypic spectrum associated with PIK3CA mutations will allow further rationalization of diagnostic schemes. PI3K signaling activates the serine/threonine kinases AKT1, AKT2 and AKT3. AKT1 is most widely expressed and is associated with growth 16 , consistent with the Proteus syndrome phenotype, whereas AKT2 is highly expressed in insulin-responsive tissues, including skeletal muscle, liver and fat, and is more closely implicated in the metabolic actions of insulin 17 . AKT3 is most highly expressed in brain and heart, with lower expression in the tissues affected in the individuals described here. Recently, somatic occurrence of mutations in both AKT2 and AKT3 encoding p.Glu17Lys, paralogous to the Proteus syndrome-associated AKT1 mutation, has been described. The AKT2 mutation causes severe insulinindependent hypoglycemia, mild asymmetric overgrowth and progressive obesity 18 , whereas the AKT3 mutation was associated with brain overgrowth 19 .
The role of AKT2 in inhibiting adipose lipolysis and stimulating glucose uptake may explain the aggressive adipose expansion observed with PIK3CA mutations compared to AKT1 mutation alone. We speculate that the paucity of adipose tissue in the non-overgrown areas of the affected individuals is caused by a chronic negative energy balance of those adipose depots, consequent upon the demands of the pathologically growing and energy-sequestering adipose tissue in affected regions. The individuals we describe do not exhibit a composite of the phenotypes associated with pathological AKT1, AKT2 and AKT3 activation, lacking key features of each condition, such as hypoglycemia, cerebriform connective tissue nevi and brain overgrowth. Some differences may be attributed to the timing and location of the founder mutation during embryogenesis. Thus, the lack of hypoglycemia and brain overgrowth likely reflects a lack of PIK3CA activation in the liver and brain, respectively, in the affected individuals in this study. Quantitative differences in the degree of activation by the different mutants of common downstream signaling pathways may also have a role, as may PI3K stimulation of non-AKT-dependent responses, including RAC-mediated cytoskeletal reorganization 20 . Some of the explanation for the phenotypic discrepancies observed with PIK3CA and AKT activation may also lie in the complexity of the PI3K enzyme: p110α is only one of three catalytic subunits coupled to RTK activation, each of which dimerizes with one of five regulatory subunits, lending substantial combinatorial complexity to PI3K function. The specificity of the coupling of different PI3K heterodimers to downstream pathways is not fully understood.
Given the prevalence of mutations in PIK3CA codon 1047 in cancer, a critical consideration is whether individuals with these mutations are at higher risk for malignancy. Several observations indicate that such mutations can initiate cancer. Circumstantial evidence for this comes from the observation of PIK3CA mutations in the early stages of some human cancers 21, 22 , whereas more direct evidence comes from mouse studies. Transgenic expression of the Pik3ca p.His1047Arg mutant in the lung 23 or breast epithelium [24] [25] [26] of mice has been shown to result in malignant tumors. However, in these studies, the Pik3ca mutant was overexpressed, potentially exaggerating its oncogenicity. Expression of Pik3ca p.His1047Arg at endogenous levels in mouse ovaries did not result in tumor formation after 1 year 27 . It is thus possible that expression at endogenous levels in the cellular context of human mesodermal lineages has more benign consequences than implied by the mouse models overexpressing mutant Pik3ca. It is of npg l e t t e r s note that oncogenic mutations in codon 1047 of PIK3CA have been reported at high prevalence in benign seborrheic keratoses and epidermal nevi in humans 28 , indicating that there is no obligate association of these mutations to malignancy. However, longitudinal studies are needed to properly assess the potential risk associated with these mutations and to formulate surveillance recommendations, should such a risk be identified.
Treatment of segmental overgrowth disorders has relied upon surgical debulking 6 and orthopedic procedures to limit growth 29 . The identification of activated PI3K-AKT signaling suggests the potential usefulness of targeted therapy, either through inhibition of PI3K, AKT or downstream pathways, such as mTORC1, using clinically available drugs, including rapamycin, which has been reported to produce major benefits in a child with somatic PTEN deficiency 30 . Intensive efforts are under way to develop novel inhibitors for use in cancer. When agents emerge with side-effect profiles that are tolerable for long-term use in patients with non-malignant disease, their use in patients with severe progressive segmental overgrowth syndromes offers the prospect of rational, mechanism-based therapy. 
URLs. Distribution of somatic mutations in

METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The two exomes from subject C1 have been deposited in the European Genome-Phenome Archive (EGA) upon approval by the Sanger Institute. Because subject C1 is readily identifiable from this study, the ethics committee did not deem it appropriate to deposit data from this individual in a publicly accessible archive. The PIK3CA reference sequence is available at GenBank under accession NM_006218.2. 
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Study procedures.
Using standard techniques, we isolated DNA from tissues and cell lines obtained either perioperatively or through punch skin biopsy of areas with overgrowth (affected) or no overgrowth distant from affected areas (unaffected). For exome sequencing, DNA libraries were prepared from affected and unaffected cells from subject C1, as described previously 32 . Genotypes were called and filtered using a Phred-like genotype quality score of ≥50 as a cutoff, which we have found to provide a pragmatic balance between sensitivity and accuracy. In brief, sequence data were filtered to leave variants that (i) were predicted to change protein sequence and (ii) were absent from dbSNP, 894 control genomes and 234 control exomes. Rare functional variants called in affected leg cells but not unaffected arm cells were verified by Sanger sequencing, first in DNA used for exome sequencing and then in DNA extracted from dermal fibroblasts established from a fresh skin biopsy. Remaining candidate pathogenic mutations were then sequenced in a panel of DNA derived from tissue samples obtained from the right leg of subject C1 after amputation. Interrogation of the codon affected by the putative pathogenic mutation was then undertaken in DNA from cells and tissues of ten additional individuals with overgrowth using Sanger sequencing and custom restriction enzyme digestion (primer sequences available on request). PIK3CA codon 1047 genotyping. Exon 21 of PIK3CA was amplified by PCR of genomic DNA and sequenced by conventional Sanger sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). Primer sequences are available on request. Quantification of mutation burden was performed using a custom PCR restriction enzyme assay as described 3 , with the following modifications. Genomic DNA was amplified and digested with the primer and restriction enzyme combinations specified in Supplementary  Table 2 . A sample was deemed positive if the height of the mutant peak was at least 100 relative fluorescence units. If in reaching this threshold, the wild-type peak was off scale, the mutation percentage was assigned a value of <1%. When using the BsaBI assay, wild-type DNA with and without restriction enzyme was used in each case to confirm complete digestion of wild-type alleles.
PIP 3 quantification. PI3K-AKT signaling was assessed, both at baseline and after stimulation with EGF in affected and unaffected dermal fibroblasts, by determining PIP 3 and PIP 2 amounts using a recently developed mass spectrometry assay 10 . In brief, dermal fibroblasts were maintained in DMEM supplemented with 10% FBS, 1,000 U/l penicillin, 0.1 g/l streptomycin and 2 mM L-glutamine and were grown to 70% confluence in six-well culture plates. Cells were serum starved in serum-free medium supplemented with 1% BSA, 1,000 U/l penicillin, 0.1 g/l streptomycin and 2 mM l-glutamine for 2 h and stimulated with either serum-free medium containing 10 nM EGF or serum-free medium alone for 5 min. The medium was aspirated, and 340 µl of 1 mM HCl was added at 4 °C. Lysates were harvested, and 10 µl of PIP 3 internal standard (provided by the Babraham Institute) was added. Then, 750 µl of kill mixture (484 ml of methanol, 242 ml of chloroform and 23.55 ml of 1 M HCl) was added to each sample before centrifugation (15,000 g for 5 min at 4 °C). Before further centrifugation, 725 µl of chloroform was added. The lower phase was collected and mixed with 708 µl of the upper phase of pre-derivitization wash mixture (240 ml of chloroform, 120 ml of methanol and 90 ml of 0.01 M HCl), and samples were again centrifuged. The resultant lower phase was collected. We added 50 µl of 2 M trimethylsilyl-diazomethane (Sigma) in hexane in a fume hood for 10 min at room temperature. The reaction was quenched with 6 µl of glacial acetic acid. We then added 700 µl of the upper phase of the post-derivitization wash (240 ml of chloroform, 120 ml of methanol and 90 ml of water) before mixing, centrifugation and collection of the lower phase. Samples were dried at room temperature and dissolved in 80 µl of methanol and 20 µl of water. Analysis was undertaken using mass spectroscopy on an MDSCI EX 400Q Trap mass spectrometer (Applied Biosystems) connected to a Prominence high-performance liquid chromatography (HPLC) system using a 1.0 × 50 mm column (Waters). The peak values of C38:4 species were expressed as a ratio (PIP 3 /PIP 2 ). Statistical analysis was performed using oneway ANOVA and Bonferroni post-hoc analyses.
Cell signaling studies. Phosphoblotting was used to assess phosphorylation of signaling intermediates of the PI3K-AKT pathway. Dermal fibroblasts were maintained and were serum starved for 16 h and stimulated with EGF as described above. Following stimulation, cells were washed with ice-cold PBS and solubilized in 80 µl of lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 30 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM Na 2 VO 4 , 1% Triton X-100, 10 mM EDTA and 1 tablet of protease inhibitor mini Complete cocktail (Roche)) per 7 ml of buffer. Protein concentration was quantified using the Bio-Rad DC protein assay. Proteins were denatured at 95 °C, resolved by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes using the iBlot system (Invitrogen). Membranes were blocked in buffer containing 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween-20 and 3% BSA for 1 h at room temperature and were probed for 16 h at 4 °C with the relevant primary antibody (Supplementary Table 3) . After washing, blots were incubated with horseradish peroxidase-conjugated secondary antibodies. Proteins were visualized by chemiluminescence (Enhanced Chemiluminescent kit, Amersham). Quantification was undertaken using Adobe PhotoShop CS3. Background subtraction was performed, and bands were quantified, taking control samples to represent baseline levels, across six separate protein blots. The mean relative integrated density in leg cells of subject C1 was 147% of the control under basal conditions and 709% following stimulation with 10 nM EGF. Statistical analysis was performed with one-way ANOVA and Bonferroni post-hoc analyses.
Fibroblasts used for infrared imaging were serum starved for 24 h before solubilization. Proteins were resolved on 10% Tris-glycine gels and transferred to nitrocellulose membranes using the iBlot system. Membranes were blocked in Odyssey blocking buffer (LiCor Biosciences) for 1 h at room temperature. Primary-antibody hybridization was performed overnight at 4 °C. After washing, blots were incubated for 1 h at room temperature in buffer containing 1:20,000 dilutions of secondary antibodies to rabbit IRDye 800CW and mouse npg
